Anisindione
drugOn this page
Also known as AnisindionaMiradonNSC-759629SID14729672SID26748631SID50086377SID170465379SID144204923
Summary
Anisindione (CHEMBL712) is an approved small-molecule anticoagulant targeting GGCX.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Targets: 1 (GGCX)
- Chemistry: 252.26 Da · C16H12O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL712 |
| Name | Anisindione |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 2197 |
| ChEBI | CHEBI:133809 |
| Molecular formula | C16H12O3 |
| Molecular weight | 252.26 |
| InChIKey | XRCFXMGQEVUZFC-UHFFFAOYSA-N |
SMILES: COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
IUPAC name: 2-(4-methoxyphenyl)indene-1,3-dione
ChEBI definition: A cyclic β-diketone consisting of indane-1,3-dione having a 4-methoxyphenyl substituent at the 4-position.
Pharmacological roles (ChEBI): anticoagulant, vitamin K antagonist.
Also known as: Anisindiona, Anisindione, Miradon, NSC-759629, SID14729672, SID26748631, ANISINDIONE, SID50086377, SID170465379, SID144204923, anisindione
Patent coverage: 699 distinct patent families (2,599 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,598 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| GGCX | γ-Glutamyl carboxylase | Inhibition | 3.8% | P38435 |
Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Microtubule-associated protein tau, Survival motor neuron protein, Inositol monophosphatase 1, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], NPC intracellular cholesterol transporter 1, Ras-related protein Rab-9A, Amine oxidase [flavin-containing] A, Prostaglandin G/H synthase 2, Polyunsaturated fatty acid 5-lipoxygenase, Prostaglandin G/H synthase 1.
Bioactivity
ChEMBL activities: 6 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| SMN1 | 5.4 | Potency | 3981 | nM | CHEMBL_ACT_3873888 |
| RAB9A | 5.35 | Potency | 4467 | nM | CHEMBL_ACT_3833537 |
| HPGD | 5.35 | Potency | 4467 | nM | CHEMBL_ACT_4805036 |
| NPC1 | 5.25 | Potency | 5623 | nM | CHEMBL_ACT_4732088 |
| P12527 | 5.04 | IC50 | 9100 | nM | CHEMBL_ACT_861791 |
| TP53 | 5 | Potency | 10000 | nM | CHEMBL_ACT_4866789 |
Target pathways
Aggregated over 1 target gene(s): GGCX.
Top Reactome pathways
2 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Gamma-carboxylation of protein precursors | 1 | GGCX |
| Defective gamma-carboxylation of F9 | 1 | GGCX |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| blood coagulation | 1 |
| cellular response to insulin stimulus | 1 |
| protein modification process | 1 |
| vitamin K metabolic process | 1 |
| glucose homeostasis | 1 |
| type B pancreatic cell proliferation | 1 |
| negative regulation of neurotransmitter secretion | 1 |
| protein maturation | 1 |
| negative regulation of bone development | 1 |
| negative regulation of testosterone biosynthetic process | 1 |
| peptidyl-glutamic acid carboxylation | 1 |
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
1 molecules share ≥1 primary target. Top 1 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| Menadione | PubChem | Approved | GGCX |